PROQR THERAPEUTICS (Germany) Probability of Future Stock Price Finishing Over 52.33
| 0PQ Stock | EUR 3.40 0.01 0.29% |
PROQR |
PROQR THERAPEUTICS Target Price Odds to finish over 52.33
The tendency of PROQR Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over € 52.33 or more in 90 days |
| 3.40 | 90 days | 52.33 | close to zero percent |
Based on a normal probability distribution, the odds of PROQR THERAPEUTICS to move over € 52.33 or more in 90 days from now is close to zero percent (This PROQR THERAPEUTICS EO 04 probability density function shows the probability of PROQR Stock to fall within a particular range of prices over 90 days) . Probability of PROQR THERAPEUTICS price to stay between its current price of € 3.40 and € 52.33 at the end of the 90-day period is about 15.87 .
Assuming the 90 days horizon PROQR THERAPEUTICS EO 04 has a beta of -2.04. This suggests as returns on its benchmark rise, returns on holding PROQR THERAPEUTICS EO 04 are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, PROQR THERAPEUTICS is expected to outperform its benchmark. In addition to that PROQR THERAPEUTICS EO 04 has an alpha of 2.0386, implying that it can generate a 2.04 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). PROQR THERAPEUTICS Price Density |
| Price |
Predictive Modules for PROQR THERAPEUTICS
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as PROQR THERAPEUTICS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.PROQR THERAPEUTICS Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. PROQR THERAPEUTICS is not an exception. The market had few large corrections towards the PROQR THERAPEUTICS's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold PROQR THERAPEUTICS EO 04, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of PROQR THERAPEUTICS within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.04 | |
β | Beta against Dow Jones | -2.04 | |
σ | Overall volatility | 0.90 | |
Ir | Information ratio | 0.10 |
PROQR THERAPEUTICS Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PROQR THERAPEUTICS for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PROQR THERAPEUTICS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| PROQR THERAPEUTICS is way too risky over 90 days horizon | |
| PROQR THERAPEUTICS appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 3.93 M. Net Loss for the year was (46.56 M) with profit before overhead, payroll, taxes, and interest of 2.4 M. | |
| PROQR THERAPEUTICS EO 04 has accumulated about 75.84 M in cash with (47.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. | |
| Roughly 21.0% of the company shares are owned by insiders or employees |
PROQR THERAPEUTICS Technical Analysis
PROQR THERAPEUTICS's future price can be derived by breaking down and analyzing its technical indicators over time. PROQR Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PROQR THERAPEUTICS EO 04. In general, you should focus on analyzing PROQR Stock price patterns and their correlations with different microeconomic environments and drivers.
PROQR THERAPEUTICS Predictive Forecast Models
PROQR THERAPEUTICS's time-series forecasting models is one of many PROQR THERAPEUTICS's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PROQR THERAPEUTICS's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about PROQR THERAPEUTICS
Checking the ongoing alerts about PROQR THERAPEUTICS for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PROQR THERAPEUTICS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| PROQR THERAPEUTICS is way too risky over 90 days horizon | |
| PROQR THERAPEUTICS appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 3.93 M. Net Loss for the year was (46.56 M) with profit before overhead, payroll, taxes, and interest of 2.4 M. | |
| PROQR THERAPEUTICS EO 04 has accumulated about 75.84 M in cash with (47.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. | |
| Roughly 21.0% of the company shares are owned by insiders or employees |
Other Information on Investing in PROQR Stock
PROQR THERAPEUTICS financial ratios help investors to determine whether PROQR Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PROQR with respect to the benefits of owning PROQR THERAPEUTICS security.